<DOC>
	<DOCNO>NCT01703299</DOCNO>
	<brief_summary>The use carbapenems , broad spectrum antibiotic last resort , become common due increase prevalence hospital community extend spectrum β-lactamase ( ESBL ) produce gram-negative bacillus ( GNB ) , include CTX-M type , resistant β-lactam antibiotic . Meanwhile , create selective pressure towards emergence strain also resistant carbapenems , place patient catastrophic situation therapeutic dead-end . A good understanding mechanism emergence BGN resistant carbapenems necessary optimize use undertake preventive measure preserve effectiveness . The aim study evaluate describe emergence carbapenem-induced resistant GNB patient intestinal microflora .</brief_summary>
	<brief_title>Emergence Resistance Intestinal Microflora During Carbapenem Treatments</brief_title>
	<detailed_description>The use carbapenems , broad spectrum antibiotic last resort , become common due increase prevalence hospital community extend spectrum β-lactamase ( ESBL ) produce gram-negative bacillus ( GNB ) , include CTX-M type , resistant β-lactam antibiotic . Meanwhile , create selective pressure towards emergence strain also resistant carbapenems , place patient catastrophic situation therapeutic dead-end . A good understanding mechanism emergence BGN resistant carbapenems necessary optimize use undertake preventive measure preserve effectiveness . Hypotheses : Carbapenems induce treat patient emergence resistant GNB intestinal flora impact colonization resistance gut microbiota . Primary objective : To determine frequency emergence carbapenems resistant GNB intestinal flora end treatment imipenem ertapenem . Secondary objective ( ) : - Assess presence carbapenem resistant GNB intestinal flora treatment . - Evaluate presence / persistence carbapenem resistant GNB intestinal flora day 3 treatment , 15 day 1 month end treatment . - Determine molecular mechanism resistance strain interest . - Describe gastrointestinal tract colonization non-commensal microorganism treatment ( impact colonization resistance ) . - Describe characteristic patient emergence resistance compare patient . - Proper conservation stool 10 patient metagenomic and/or metatranscriptomic analysis change intestinal flora . Primary endpoint : Presence carbapenem resistant GNB stool end treatment patient , culture selective medium . Secondary endpoint : - Presence carbapenem resistant GNB stool treatment , day 3 15 day 1 month stop treatment , culture selective medium . - PCR sequence resistance gene strain interest . - Colonization digestive tract non-commensal microorganism treatment . - Characteristics patient without emergence resistance .</detailed_description>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>age &gt; = 18 year old hospitalize initiating treatment imipenem ertapenem faeces harvest begin treatment write informed consent patient relative patient incapable express his/her consent reachable phone hospitalization ( patient able express consent ) . Exclusion Criteria : hospitalize intensive care unit concomitant antibiotic treatment ( except aminosid vancomycin le 4 day ) . Secondary exclusion criterion : introduction antibiotic carbapenem treatment ( except vancomycin aminosid ) vancomycin treatment 4 day carbapenem treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>imipenem</keyword>
	<keyword>ertapenem</keyword>
	<keyword>resistance</keyword>
	<keyword>commensal flora</keyword>
</DOC>